We confirmed this by Western blotting (Figure 1H) and showed that desARE3’UTR ERBB2-3 significantly degraded ERBB2 expression and desARE3’UTR ERBB2-30 led to more than 70% significant downregulation of ERBB2 protein expression in the ERBB2+ trastuzumab-resistant breast cancer cells compared to wildtype and vector control cells (Figure 1H; Supplementary Figure S1F). This evidence concerns the gene ERBB2 and breast carcinoma.